Newsroom

Recent News Releases

April 15, 2019 4/15/2019 Takeda Announces Top-Ranked Investment Analyst Atsushi Seki to Join Takeda

April 1, 2019 4/1/2019 European Medicines Agency Accepts Takeda’s Marketing Authorization Application for a Subcutaneous Formulation of Vedolizumab for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease

March 26, 2019 3/26/2019 Takeda Presents New Data at the Endocrine Society's 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism

March 9, 2019 3/9/2019 Vedolizumab (Entyvio^®) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira^®) in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis

February 20, 2019 2/20/2019 Takeda's Sustainability Activities Receive Multiple Accolades by Rigorous ESG Evaluators

SEE ALL NEWS AND RELEASES >

・For legacy Shire information, click here

Featured Topics

CEO Christophe Weber on Why Takeda’s Unique Corporate Governance Structure Works

LEARN MORE

Andy Plump on pushing the boundaries of science within the “new” Takeda R&D community

LEARN MORE

Ramona Sequeira, President of Takeda's U.S. Business Unit, on the many opportunities that lie ahead for the “new” Takeda

LEARN MORE

Embracing diversity and inclusion in an expanding global workplace

LEARN MORE

Celebrating Our New Global Reach

LEARN MORE

SEE ALL FEATURED TOPICS ARTICLES >

In the News

With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.

LEARN MORE

Executive Leadership

Meet our Executive Leadership Team led by our President and CEO, Christophe Weber

LEARN MORE

For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.